MediciNova, Inc. develops small-molecule therapeutics for inflammatory, fibrotic, and neurodegenerative diseases. The company's recurring updates center on MN-166, or ibudilast, and MN-001, or tipelukast, including programs involving amyotrophic lateral sclerosis, degenerative cervical myelopathy, progressive multiple sclerosis, chemotherapy-induced peripheral neuropathy, Long COVID, substance dependence, non-alcoholic fatty liver disease, hypertriglyceridemia, and idiopathic pulmonary fibrosis.
MediciNova news also covers clinical-trial progress, expanded-access activity, investigator-sponsored research, peer-reviewed translational studies, scientific and regulatory advisory matters, and corporate updates connected to its Nasdaq-listed common stock and Tokyo Stock Exchange listing.
MediciNova has entered a collaboration with BioComo and Mie University to co-develop a SARS-CoV-2 vaccine utilizing the BC-PIV vector technology. This innovative approach employs a recombinant human parainfluenza virus type 2, which showcases high immunogenicity and safety in producing vaccines. The partnership is positioned to leverage previous successes in vaccine development, including for Ebola and Respiratory Syncytial virus. The vaccine aims to be available in both intra-nasal and intra-muscular formats to enhance local immunity against COVID-19.
MediciNova, a biopharmaceutical company traded on NASDAQ (MNOV), announced that Geoffrey O'Brien will join a panel at the B. Riley FBR Virtual Infectious Disease Summit on July 21, 2020.
O'Brien will discuss treatment strategies for COVID-19, including the clinical development of MN-166 (ibudilast) aimed at preventing acute respiratory distress syndrome (ARDS). The FDA has accepted the Investigational New Drug Application for MN-166, allowing its clinical trial to proceed, focusing on hospitalized COVID-19 patients at risk for ARDS.
MediciNova, Inc. announced the FDA's acceptance of its Investigational New Drug Application (IND) for MN-166 (ibudilast), aimed at preventing Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. This opens the path for clinical trials targeting hospitalized patients at risk for ARDS, leveraging MN-166's anti-inflammatory and anti-thrombotic potential. The Phase 2 trial will assess safety, tolerance, and efficacy over 7 days, with key objectives focused on respiratory failure and plasma cytokine levels.
MediciNova announced positive preclinical findings for MN-166 (ibudilast) as an adjunct treatment for glioblastoma, published in Frontiers in Immunology. The study shows MN-166 effectively reduces myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment, enhancing CD8 T cell activity. Clinical trials are underway combining MN-166 with temozolomide, showing improved survival rates in animal models. Glioblastoma is a severe brain cancer with a median survival of 11-15 months. MediciNova aims to revolutionize treatment options for this aggressive cancer.
MediciNova, Inc. announced the receipt of a Notice of Intention to Grant from the European Patent Office for a pending patent application covering MN-001 (tipelukast) and its metabolite MN-002. This patent will address treatments for hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia, expiring no earlier than July 2034. The patent claims include methods for reducing triglyceride and cholesterol blood levels through oral administration. This development could enhance the potential market value of MN-001, complementing existing patents in the U.S., Japan, and China.